ERBB2 and neoplasm: These molecular changes did not result in altered hormone receptor status, all tumours displayed the same ER/PR/HER2 phenotype in both primary and metastatic sites and these were representative of the phenotypes described when the tumours were originally isolated from patients (Additional file 2: Figure S2) [18].